SFPM
OREX

Sensible Financial Planning & Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sensible Financial Planning & Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7
Closed – – 80
2016
Q3 		$0 Buy
+7
New +$26 ﹤0.01% 87

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sensible Financial Planning & Management's OREX Position: Q4 2016 in Review

Sensible Financial Planning & Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2016, closing a stake of 7 shares.

Sensible Financial Planning & Management first reported a position in OREX in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

  • Sensible Financial Planning & Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Sensible Financial Planning & Management sold 7 Orexigen Therapeutics, Inc. shares in Q4 2016.
  • Sensible Financial Planning & Management first reported a position in Orexigen Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Sensible Financial Planning & Management's Orexigen Therapeutics, Inc. position peaked at $0 in Q3 2016.
  • 53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on Sensible Financial Planning & Management's 13F filing for Q4 2016, filed 6 Feb 2017.